New class of menopause drugs reduces number and severity of hot flushes

March 14, 2018, Imperial College London

A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days.

The treatment, tested by scientists at Imperial College London, also reduces the severity of hot flushes by over a third within three days of taking it.

The research, funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), is a new in-depth analysis of data collected from a clinical trial initially published last year.

The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.

The original trial, which was a randomised, double-blind, placebo-controlled trial, involved 37 menopausal women aged between 40 and 62 years old - and who experienced seven or more hot flushes a day.

Participants were randomly chosen to first receive either an 80mg daily dose of the drug, called MLE4901, or a placebo over the course of a four-week period. They then switched to receive the other tablet for an additional four weeks. This ensured the women acted as their own controls during the study, and the effects of the drug were clear.

The researchers found that the compound MLE4901 significantly reduced the average total number of flushes during the four-week treatment period, as well as their severity, compared to when the patients received the placebo for four weeks.

The new analysis shows the compound has a significant effect within just three days explains Professor Waljit Dhillo, an NIHR Research Professor from the Department of Medicine at Imperial: "We already knew this compound could be a game-changer for , and get rid of three-quarters of their hot flushes in four weeks. But this new analysis confirms the beneficial effect is obtained very quickly - within just three days."

Professor Dhillo explains this specific compound will not be taken further in trials, due to side effects that may affect liver function. However, two very similar drugs, which also block NKB but do not appear to carry these side effects have entered larger patient trials, with one such trial launched in the US last year.

The menopause occurs when oestrogen levels fall, typically around 45 to 55 years of age, which leads to periods stopping, the inability to have children naturally, and a number of physical changes, including menopausal flushing and/or sweating.

For many women, these hot flushes may be little more than an uncomfortable inconvenience. But for some, frequent severe episodes can lead to clothes and bed sheets drenched in sweat, as well as relentless waking from sleep which impacts their working, social and home lives.

The new experimental are thought to work by blocking the action of a brain chemical called neurokinin B (NKB). Previous animal and human trials have shown increased levels of NKB may trigger hot flushes. The drug compound is thought to prevent NKB activating temperature control areas within the brain - which appears to halt hot flushes.

The new data also revealed that the drug was as effective at improving daytime flush symptoms as it was at improving night time symptoms. Furthermore, the women reported a 82 percent decrease in the amount their hot flushes interrupted their sleep, and a 77 percent reduction in interruption to their concentration.

However, the team says further research is needed to reveal whether improvements in sleep and concentration were simply due to less disruption from hot flushes, or if the compound also affected sleep and concentration pathways in the brain.

Dr Julia Prague, first author of the study, explained: "As NKB has many targets of action within the brain the potential for this drug class to really improve many of the symptoms of the menopause, such as , difficulty sleeping, weight gain, and poor concentration, is huge. To see the lives of our participants change so dramatically and so quickly was so exciting, and suggests great promise for the future of this new type of treatment."

The hope is these types of compounds may provide women with an alternative to Hormone Replacement Therapy, the current treatment for symptoms of the menopause. This therapy, which contains oestrogen, may increase the relative risk of breast cancer and can increase the risk of blood clots. This means that many women cannot take HRT to relieve their menopausal symptoms.

Professor Dhillo added: "This class of new drugs may provide women with a much-needed alternative to HRT. "

He added that the discovery of this class of compound, which was previously developed as a drug for schizophrenia, highlights the importance of collaboration and investment in British research.

Professor Dhillo said: "Thanks to Government funding from the MRC and NIHR, and collaboration with pharmaceutical companies, we were able to identify this new therapeutic use for the compound - which had previously been sitting on the shelf unused - and within three years show this type of drug may make a tangible difference to the lives of millions of ."

Explore further: New experimental drug offers hope for menopausal women with frequent hot flushes

Related Stories

New experimental drug offers hope for menopausal women with frequent hot flushes

April 3, 2017
Women plagued by frequent hot flushes during the menopause could cut the number of flushes by almost three-quarters, thanks to a new drug compound.

Self-compassion helps to cope with symptoms of menopause

June 5, 2014
(Medical Xpress)—Menopausal women with high self-compassion may find that hot flushes interfere less with their lives, according a new study.

Menopause symptoms are associated with poor self-assessed work ability

April 29, 2016
A novel study from researchers at Monash University has found that poorer work ability and women's self-assessed work ability was significantly associated with having menopausal hot flushes and night sweats.

Do meds like Remifemin really ease hot flushes and night sweats in menopausal women?

April 17, 2017
If you see a female friend or colleague sitting in front of a desk fan in winter while everyone else is shivering in sweaters, chances are she is having a hot flush, courtesy of the menopause.

Study shines new light on menopause symptoms

April 16, 2013
(Medical Xpress)—New UQ research reveals menopausal women who gain weight, smoke and consume alcohol at risky levels face an increased risk of experiencing night sweats and hot flushes.

Sleep problems in menopause linked to hot flashes, depression, and may not last

February 20, 2018
Sleep disruptions are one of the most commonly reported complaints among menopausal women. A new study of middle-aged women found that sleep problems vary across the stages of menopause, yet are consistently correlated with ...

Recommended for you

Accurate measurements of sodium intake confirm relationship with mortality

June 21, 2018
Eating foods high in salt is known to contribute to high blood pressure, but does that linear relationship extend to increased risk of cardiovascular disease and death? Recent cohort studies have contested that relationship, ...

Fruit and vegetables linked to changes in skin colour, new research finds

June 21, 2018
Skin colour in young Caucasian men is strongly linked to high levels of fruit and vegetable consumption, new research by Curtin University has found.

Fans of yoga therapy have yet to win over doctors

June 21, 2018
Yoga practitioners often tout the unique health benefits of the ancient discipline—from relieving stress and pain to improving vascular health—but most doctors remain sceptical in the absence of hard proof.

Medicaid work requirements and health savings accounts may impact people's coverage

June 20, 2018
Current experimental approaches in Medicaid programs—including requirements to pay premiums, contribute to health savings accounts, or to work—may lead to unintended consequences for patient coverage and access, such ...

What a pain: The iPad neck plagues women more

June 20, 2018
Is your iPad being a literal pain in the neck?

Introduction of alcohol found to adversely impact fertility rates in hunter-gatherer community

June 19, 2018
Fernando Ramirez Rozzi, a research director with the French National Centre for Scientific Research has found that the introduction of alcohol to a Baka pygmy hunter-gatherer society caused fertility rates to fall. In his ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.